Understanding how bladder cancer affects the immune system
Molecular Mechanisms of Bladder Cancer Immunometabolism
This study is looking at how certain cells and molecules in bladder cancer might be making it harder for the immune system to fight the disease, with the hope of finding new ways to improve treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11007268 on NIH RePORTER |
What this research studies
This research investigates the molecular mechanisms that contribute to the immune suppression seen in bladder cancer. It focuses on the role of tumor-resident Schwann cells and specific long non-coding RNAs that may influence the tumor microenvironment and immune response. By exploring these interactions, the research aims to identify new therapeutic targets that could enhance the effectiveness of immunotherapy for bladder cancer patients. The ultimate goal is to develop strategies that can overcome the resistance of bladder cancer to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bladder cancer, particularly those whose tumors are resistant to current immunotherapy treatments.
Not a fit: Patients with non-bladder cancers or those whose bladder cancer is already responding well to existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for bladder cancer patients, improving their treatment outcomes.
How similar studies have performed: Previous research has shown promise in targeting immune suppression in other cancers, suggesting that this approach may also be effective for bladder cancer.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Yang, Liuqing — University of Tx Md Anderson Can Ctr
- Study coordinator: Yang, Liuqing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.